抗HER2治疗在转移性结直肠癌中的研究进展

doi:10.11904/j.issn.1002-3070.2022.03.018

摘要/Abstract

摘要： 结直肠癌(Colorectal cancer,CRC)是世界第三大常见癌症和第二大癌症相关死亡原因,严重威胁人类生命健康。尽管接受早期诊断和治疗,仍有相当部分结直肠癌患者因发生转移而预后较差。针对结直肠癌分子多样性的研究不但可指导预后,对患者个体化管理亦有重要参考意义。人表皮生长因子受体2(Human epidermal growth factor receptor-2,HER2)在乳腺癌、胃癌等多种恶性肿瘤中表达,抗HER2治疗能有效改善HER2阳性晚期乳腺癌、胃癌患者的预后。HER2作为转移性结直肠癌(metastatic colorectal cancer,mCRC)新兴的生物标志物近年来也备受关注。本文就目前HER2阳性mCRC的诊疗现状研究进展做一综述,以期为临床诊断、药物选择等提供参考。

关键词: 转移性结直肠癌, 人表皮生长因子受体2, 精准医学, 靶向治疗

Abstract: Colorectal cancer(CRC)is the third most common cancer and the second largest cause of cancer-related deaths in the world,which seriously threatens human life and health.Despite early diagnosis and treatment,a considerable number of CRC patients have a poor prognosis due to metastasis.Research on the molecular diversity of CRC not only guides the prognosis,but it also has an important reference significance for the individualized treatment of patients.Human epidermal growth factor receptor-2(HER2)is expressed in breast cancer,gastric cancer and other malignant tumors.Anti-HER2 treatment can effectively improve the prognosis of patients with HER2-positive advanced breast cancer and gastric cancer.HER2,as an emerging biomarker of metastatic colorectal cancer(mCRC),has also attracted much attention in recent years.This article reviews the current research progress in the diagnosis and treatment of HER2-positive mCRC,with a view to providing references for clinical diagnosis and drug selection.

Key words: Metastatic colorectal cancer, Human epidermal growth factor receptor-2, Precision medicine, Targeted therapy

中图分类号:

R735.3

陈素, 隋红. 抗HER2治疗在转移性结直肠癌中的研究进展[J]. 实用肿瘤学杂志, 2022, 36(3): 288-292.

CHEN Su, SUI Hong. Research progress of anti-HER2 therapy in metastatic colorectal cancer[J]. Journal of Practical Oncology, 2022, 36(3): 288-292.

0
/ / 推荐

导出引用管理器 EndNote|Reference Manager|ProCite|BibTeX|RefWorks

链接本文: http://journal09.magtechjournal.com/Jwk3_syzlxzz/CN/10.11904/j.issn.1002-3070.2022.03.018

http://journal09.magtechjournal.com/Jwk3_syzlxzz/CN/Y2022/V36/I3/288

参考文献

1 Sung H,Ferlay J,Siegel RL,et al.Global cancer statistics 2020:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J].CA Cancer J Clin,2021,71(3):209-249.
2 Siegel RL,Miller KD,Goding Sauer A,et al.Colorectal cancer statistics[J].CA Cancer J Clin,2020,70(3):145-164.
3 Li QH,Wang YZ,Tu J,et al.Anti-EGFR therapy in metastatic colorectal cancer:mechanisms and potential regimens of drug resistance[J].Gastroenterol Rep(Oxf),2020,8(3):179-191.
4 Wells A.EGF receptor[J].Int J Biochem Cell Biol,1999,31(6):637-643.
5 Schechter AL,Stern DF,Vaidyanathan L,et al.The neu oncogene:an erb-B-related gene encoding a 185,000-Mr tumour antigen[J].Nature,1984,312(5994):513-516.
6 King C,Hristova K.Direct measurements of VEGF-VEGFR2 binding affinities reveal the coupling between ligand binding and receptor dimerization[J].J Biol Chem,2019,294(23):9064-9075.
7 Richman SD,Southward K,Chambers P,et al.HER2 overexpression and amplification as a potential therapeutic target in colorectal cancer:analysis of 3256 patients enrolled in the QUASAR,FOCUS and PICCOLO colorectal cancer trials[J].J Pathol,2016,238(4):562-570.
8 Ross JS,Fakih M,Ali SM,et al.Targeting HER2 in colorectal cancer:the landscape of amplification and short variant mutations in ERBB2 and ERBB3[J].Cancer,2018,124(7):1358-1373.
9 Loree JM,Bailey AM,Johnson AM,et al.Molecular landscape of ERBB2/ERBB3 mutated colorectal cancer[J].J Natl Cancer Inst,2018,110(12):1409-1417.
10 Siena S,Sartore-Bianchi A,Marsoni S,et al.Targeting the human epidermal growth factor receptor 2(HER2)oncogene in colorectal cancer[J].Ann Oncol,2018,29(5):1108-1119.
11 Bertotti A,Migliardi G,Galimi F,et al.A molecularly annotated platform of patient-derived xenografts("xenopatients")identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer[J].Cancer Discov,2011,1(6):508-523.
12 Yonesaka K,Zejnullahu K,Okamoto I,et al.Activation of ERBB2 signaling causes resistance to the EGFR-directed therapeutic antibody cetuximab[J].Sci Transl Med,2011,3(99):99ra86.
13 Li JL,Lin SH,Chen HQ,et al.Clinical significance of HER2 and EGFR expression in colorectal cancer patients with ovarian metastasis[J].BMC Clin Pathol,2019,19:3.
14 Kavuri SM,Jain N,Galimi F,et al.HER2 activating mutations are targets for colorectal cancer treatment[J].Cancer Discov,2015,5(8):832-841.
15 Sartore-Bianchi A,Trusolino L,Martino C,et al.Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory,KRAS codon 12/13 wild-type,HER2-positive metastatic colorectal cancer(HERACLES):a proof-of-concept,multicentre,open-label,phase 2 trial[J].Lancet Oncol,2016,17(6):738-746.
16 Sawada K,Nakamura Y,Yamanaka T,et al.Prognostic and predictive value of HER2 amplification in patients with metastatic colorectal cancer[J].Clin Colorectal Cancer,2018,17(3):198-205.
17 Pathmanathan N,Bilous AM.HER2 testing in breast cancer:an overview of current techniques and recent developments[J].Pathology,2012,44(7):587-595.
18 Wolff AC,Hammond MEH,Allison KH,et al.Human epidermal growth factor receptor 2 testing in breast cancer:American society of clinical oncology/college of American pathologists clinical practice guideline focused update[J].J Clin Oncol,2018,36(20):2105-2122.
19 El-Deiry WS,Goldberg RM,Lenz HJ,et al.The current state of molecular testing in the treatment of patients with solid tumors,2019[J].CA Cancer J Clin,2019,69(4):305-343.
20 Valtorta E,Martino C,Sartore-Bianchi A,et al.Assessment of a HER2 scoring system for colorectal cancer:results from a validation study[J].Mod Pathol,2015,28(11):1481-1491.
21 Liu F,Ren C,Jin Y,et al.Assessment of two different HER2 scoring systems and clinical relevance for colorectal cancer[J].Virchows Arch,2020,476(3):391-398.
22 Che YQ,Zhang Y,Ou KP,et al.Depth of response and early tumor shrinkage for predicting clinical outcomes in HER2-positive metastatic breast cancer treated with trastuzumab[J].Cancer Manag Res,2020,12:8527-8534.
23 Hsu A,Chudasama R,Almhanna K,et al.Targeted therapies for gastroesophageal cancers[J].Ann Transl Med,2020,8(17):1104.
24 Tosi F,Sartore-Bianchi A,Lonardi S,et al.Long-term clinical outcome of trastuzumab and lapatinib for HER2-positive metastatic colorectal cancer[J].Clin Colorectal Cancer,2020,19(4):256-262.
25 Hainsworth JD,Meric-Bernstam F,Swanton C,et al.Targeted therapy for advanced solid tumors on the basis of molecular profiles:results from mypathway,an open-label,phase IIa multiple basket study[J].J Clin Oncol,2018,36(6):536-542.
26 Meric-Bernstam F,Hurwitz H,Raghav KPS,et al.Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer(MyPathway):an updated report from a multicentre,open-label,phase 2a,multiple basket study[J].Lancet Oncol,2019,20(4):518-530.
27 Lee A.Tucatinib:first approval[J].Drugs,2020,80(10):1033-1038.
28 Lee KAP,Taylor J,Rosler R,et al.Preclinical activity of HER2-selective tyrosine kinase inhibitor tucatinib as a single agent or in combination with trastuzumab or docetaxel in solid tumor models[J].Mol Cancer Ther,2020,19(4):976-987.
29 Strickler JH,Zemla T,Ou FS,et al.Trastuzumab and tucatinib for the treatment of HER2 amplified metastatic colorectal cancer(mCRC):Initial results from the MOUNTAINEER trial[J].Ann Oncol,2019,30(suppl 5):200.
30 Greally M,Kelly CM,Cercek A.HER2:an emerging target in colorectal cancer[J].Curr Probl Cancer,2018,42(6):560-571.
31 Sartore-Bianchi A,Lonardi S,Martino C,et al.Pertuzumab and trastuzumab emtansine in patients with HER2-amplified metastatic colorectal cancer:the phase II HERACLES-B trial[J].ESMO Open,2020,5(5):e000911.
32 Siena S,Di Bartolomeo M,Raghav KPS,et al.A Phase II,multicenter,open-label study of trastuzumab deruxtecan(T-DXd;DS-8201)in patients(pts)with HER2-expressing metastatic colorectal cancer(mCRC):DESTINY-CRC01[J].J Clin Oncol,2021,22(6):779-789.
33 Hausman DF,Hamilton EP,Beeram M,et al.Phase 1 study of ZW25,a bispecific anti-HER2 antibody,in patients with advanced HER2-expressing cancers[J].J Clin Oncol,2017,35(suppl 4):215.

[1]	郑艳丽, 贺建霞. 弥漫大B细胞淋巴瘤的DNA甲基化改变及治疗进展[J]. 实用肿瘤学杂志, 2022, 36(3): 259-262.
[2]	吴芳芳, 郑桐森. 胆道恶性肿瘤辅助治疗的研究现状及展望[J]. 实用肿瘤学杂志, 2022, 36(2): 156-161.
[3]	侯建勋, 王洪斌. 外泌体对乳腺癌诊疗一体化影响的研究进展[J]. 实用肿瘤学杂志, 2022, 36(2): 178-182.
[4]	史润泽, 李志高. 三阴性乳腺癌各亚型精准医疗策略研究进展[J]. 实用肿瘤学杂志, 2021, 35(6): 529-533.
[5]	马补换, 刘彩霞. Jagged1促进乳腺癌发生发展及远处转移的研究进展[J]. 实用肿瘤学杂志, 2021, 35(5): 452-457.
[6]	杨思琦,宋启斌,李清清(综述),姚颐(审校). 靶向抑制FGFRs信号在治疗恶性肿瘤中的研究进展[J]. 实用肿瘤学杂志, 2021, 35(1): 73-77.
[7]	宋家羽, 冯越, 王棹, 张云艳. 外泌体与妇科恶性肿瘤相关性的最新研究进展[J]. 实用肿瘤学杂志, 2020, 34(6): 571-575.
[8]	范晓娜, 王丹, 黎清炜, 李志伟. 胰腺癌术后辅助药物治疗的研究进展[J]. 实用肿瘤学杂志, 2020, 34(3): 249-253.
[9]	刘超, 郑桐森. 新冠肺炎时期肿瘤内科工作的总结和反思[J]. 实用肿瘤学杂志, 2020, 34(2): 100-102.
[10]	李国政, 庞达. HER2阳性乳腺癌治疗的研究进展[J]. 实用肿瘤学杂志, 2020, 34(1): 74-78.
[11]	左志博, 郭志琴, 王振, 杨宏杰, 邬万新. Semaphorin 3F在肿瘤中的研究进展[J]. 实用肿瘤学杂志, 2020, 34(1): 88-92.
[12]	朱琳,张春霞. 纳米载药系统靶向肿瘤干细胞的研究进展[J]. 实用肿瘤学杂志, 2019, 33(3): 276-279.
[13]	方琳, 刘超, 张纯慧, 张艳桥. 转移性结直肠癌维持治疗的研究现状与治疗策略[J]. 实用肿瘤学杂志, 2019, 33(2): 173-178.
[14]	李悦, 徐可, 韩增祥, 孙敏, 樊国华综述, 张勇审校. 结肠癌中肿瘤相关巨噬细胞的作用及靶向治疗的研究进展[J]. 实用肿瘤学杂志, 2018, 32(5): 450-454.
[15]	王元综述, 孙轶华审校. β-连环蛋白在软组织肿瘤中的研究进展[J]. 实用肿瘤学杂志, 2018, 32(5): 455-459.